Michael R. Cooper

A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.

W. Figg, D. Headlee, A. Tompkins, 1994, Cancer research.

Effect of suramin on human prostate cancer cells in vitro.

W. Linehan, R. Danesi, C. Jamis-Dow, 1991, The Journal of urology.

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.

O. Sartor, W. Figg, E. Reed, 1995, The American journal of medicine.

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.

S. Steinberg, W. M. Linehan, O. Sartor, 1994, Journal of the National Cancer Institute.

A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer : toxicity and response

O. Sartor, W. Figg, D. Headlee, 1996, Cancer Chemotherapy and Pharmacology.

Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.

S. Steinberg, E. Sausville, O. Sartor, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.